Daxor Corporation (DXR)
| Bid | 7 |
| Market Cap | 37.63M |
| Revenue (ttm) | 767.06K |
| Net Income (ttm) | 536.33K |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -86.44 |
| Forward PE | 49.18 |
| Analyst | Strong Buy |
| Ask | 7.93 |
| Volume | 3,696 |
| Avg. Volume (20D) | 6,944 |
| Open | 7.31 |
| Previous Close | 7.38 |
| Day's Range | 7.25 - 7.79 |
| 52-Week Range | 6.55 - 10.00 |
| Beta | -0.06 |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 221.34% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
TruLite Health Bolsters Health Equity Expertise with Expanded Leadership TeamTEMPE, Ariz.--(BUSINESS WIRE)--TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intellige...